Fig. 3

Longitudinal monitoring of circulating CAR T transgenes and correlation with tumor responses. A CAR T transgenes ddPCR monitoring and correlation with tumor responses in subgroup of patients who achieved an objective response following treatment with ide-cel. The observed results suggest that higher expansion levels in the first 4 weeks following ide-cel infusion correlate with better tumor responses. B CAR T transgenes ddPCR dynamics for the 5 patients showing PD. The observed results suggest that higher expansion levels in the first 4 weeks following ide-cel infusion correlate with better tumor responses. Green: patients with sCR; Blue: patients with CR; Magenta: patients with VGPR; red: patients with PD. C Tumor responses in patients with higher CAR T expansion (> 10⁵ CAR T copies/μg cfDNA) vs lower CAR T expansion (< 10⁵ CAR T copies/μg cfDNA). Abbreviations: CR: complete response; PD: progressive disease; sCR: stringent complete response; VGPR: very good partial response